REZOLUTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.03 USD | -2.89% |
|
+13.20% | +306.05% |
| 22/05 | Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell | MT |
| 22/05 | Top Premarket Gainers | MT |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the Rezolute, Inc. Annua...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
Calendar
06/06/2024
- Jefferies Global Healthcare Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.03
USD
Average target price
10
USD
Spread / Average Target
+148.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +306.05% | 162M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- RZLT Stock
- News Rezolute, Inc.
- Transcript : Rezolute, Inc. - Shareholder/Analyst Call
